Oksana Sergeeva
Company: EvolveImmune Therapeutics, Inc.
Job title: Principal Scientist - Translational Science
Seminars:
EVOLVE104: A First-In-Category T-Cell Engager with Integrated CD2 Costimulation Targets ULBP2/5/6-Expressing Solid Tumors 4:45 pm
The integration of CD2 costimulation and carefully affinity-tuned CD3 binding mediate improved potency and superior efficacy of EVOLVE104 over conventional bispecific and clinical comparators The preclinical data demonstrate safety, efficacy, and developability of EVOLVE104, and support the upcoming Phase I clinical study ULBP2/5/6 is a novel target which is enriched on squamous cell tumors and…Read more
day: Day 1